Hancock Whitney Corp Has $1.24 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Hancock Whitney Corp raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 11.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,733 shares of the biotechnology company’s stock after acquiring an additional 4,915 shares during the quarter. Hancock Whitney Corp’s holdings in Exelixis were worth $1,239,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. V Square Quantitative Management LLC bought a new stake in Exelixis in the 3rd quarter valued at $30,000. Park Place Capital Corp bought a new stake in shares of Exelixis in the second quarter valued at approximately $45,000. GAMMA Investing LLC grew its position in Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares in the last quarter. Capital Performance Advisors LLP bought a new position in Exelixis during the 3rd quarter worth $61,000. Finally, Essex Investment Management Co. LLC acquired a new position in Exelixis in the 3rd quarter valued at $74,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Trading Up 0.2 %

EXEL stock opened at $36.45 on Wednesday. The firm has a market cap of $10.41 billion, a PE ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.51. The stock has a 50-day moving average price of $30.08 and a 200-day moving average price of $25.73. Exelixis, Inc. has a 1-year low of $19.20 and a 1-year high of $36.72.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 earnings per share. On average, analysts forecast that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Insider Buying and Selling

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the sale, the executive vice president now owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. This trade represents a 3.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the transaction, the executive vice president now owns 498,945 shares in the company, valued at approximately $15,666,873. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 279,736 shares of company stock valued at $9,308,410 over the last ninety days. 2.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on EXEL shares. Stifel Nicolaus increased their price objective on shares of Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, October 16th. Morgan Stanley boosted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, October 11th. Wells Fargo & Company lifted their price target on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price objective on shares of Exelixis in a research note on Wednesday, October 30th. Finally, TD Cowen boosted their price objective on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.44.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.